Foghorn Therapeutics Inc.
NASDAQ:FHTXBiotechnology
+$0.10 today
- Market cap
- $107.33M
- Beta
- 2.89
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$1.08
Volume 0.53M
Average 0.15M
FHTX EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Foghorn Therapeutics Inc.NASDAQ: FHTX
EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026
EPS (Basic) remains negative
Q1 FY2026 EPS (Basic) was -$0.29, compared with -$0.3 a year earlier. Trailing-twelve-month EPS (Basic) was -$1.17.
Context
- EPS (Basic) grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 4 analysts of -$0.08 (+93.0%) for the fiscal year ending Dec 2026, a step up from the +25.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.29+17.1% QoQ
- Last fiscal yearDec 2025
- -$1.18+25.3% YoY
- LTMMar 2026
- -$1.17+14.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +3.3% | +12.5% | +9.2 pp |
| 1 year | +25.3% | +93.0% | +67.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (1.18) USD
- Year-over-year change
- +25.3%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.18) | +25.3% |
| FY2024 | 2024-12-31 | (1.58) | +32.5% |
| FY2023 | 2023-12-31 | (2.34) | +10.7% |
| FY2022 | 2022-12-31 | (2.62) | +5.8% |
| FY2021 | 2021-12-31 | (2.78) | — |
EPS (Basic) vs competitors
How FHTX compares with its peers on the latest reported figures
- FHTX's LTM Mar 2026 EPS (Basic) of -$1.17 is the 4th highest of the 11 companies compared; the peer median is -$1.33.
- Its year-over-year change of +14.6% is the 7th highest of 11, against a peer median of +15.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | -$0.58 | +90.9% | — | |
| LTM Mar 2026 | -$0.59 | +14.6% | — | |
ZURAZura Bio Limited | LTM Mar 2026 | -$1.09 | -43.4% | — |
| LTM Mar 2026 | -$1.17 | +14.6% | — | |
| LTM Mar 2026 | -$1.17 | +40.3% | — | |
| LTM Mar 2026 | -$1.31 | +16.6% | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | -$1.35 | +23.3% | — |
| LTM Mar 2026 | -$2.74 | +39.6% | — | |
| LTM Mar 2026 | -$2.83 | -11.9% | — | |
| LTM Mar 2026 | -$4 | -561.0% | — | |
| LTM Mar 2026 | -$4.05 | -437.5% | — | |
| Peer median (excluding FHTX) | -$1.33 | +15.6% | — | |
Competitors are the stored peer set for FHTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.32M | 19.23M | 34.16M | 22.6M | 30.91M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 3.33M |
| Gross Profit | 1.32M | 19.23M | 34.16M | 22.6M | 27.58M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 89.2% |
| Research & Development | 80.33M | 105.62M | 109.69M | 94.53M | 85.47M |
| Selling, General & Admin | 21.73M | 30.75M | 32.37M | 28.36M | 27.55M |
| Operating Expenses | 102.05M | 136.37M | 142.06M | 125.29M | 109.68M |
| Depreciation & Amortization | 3.23M | 3.32M | 3.45M | 3.12M | 3.33M |
| EBITDA | (96.19M) | (105.56M) | (90.75M) | (97.17M) | (70.95M) |
| EBITDA Margin | -7292.4% | -549.0% | -265.7% | -429.9% | -229.5% |
| Operating Income | (100.73M) | (117.14M) | (107.91M) | (102.68M) | (82.11M) |
| Operating Margin | -7637.1% | -609.2% | -315.9% | -454.3% | -265.6% |
| Interest Income | 59K | 5.68M | 10.88M | 11.9M | 8.75M |
| Interest Expense | 1.91M | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (586K) | 8.26M | 13.71M | 16.06M | 7.82M |
| Income Before Tax | (101.32M) | (108.88M) | (94.2M) | (86.62M) | (74.28M) |
| Pre-Tax Margin | -7681.6% | -566.3% | -275.8% | -383.2% | -240.3% |
| Income Tax Expense | 0 | 0 | 4.23M | 0 | 0 |
| Net Income | (101.32M) | (108.88M) | (98.43M) | (86.62M) | (74.28M) |
| Net Margin | -7681.6% | -566.3% | -288.2% | -383.2% | -240.3% |
| EPS (Basic) | (2.78) | (2.62) | (2.34) | (1.58) | (1.18) |
| EPS (Diluted) | (2.78) | (2.62) | (2.34) | (1.58) | (1.18) |
| Weighted Avg Shares | 37.17M | 41.59M | 41.97M | 54.9M | 62.98M |
| Weighted Avg Shares (Diluted) | 37.17M | 41.59M | 41.97M | 54.9M | 62.98M |
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Intrinsic Alpha fair value
Locked
Current Price
$1.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.